Tiziana Life Sciences Ltd (TLSA)
Nasdaq · Healthcare · Biotechnology
$1.07−4.46%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $136M
- 52-week range
- $0.76 – $2.33
- 52-week change
- −43.15%
- EPS (trailing)
- −$0.16
- Analyst rating
- 1.0 Strong buy
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Headquarters: London, United Kingdom · 10 employees · tizianalifesciences.com